(Q34623149)

3 August 2017

title

Improved virological response to highly active antiretroviral therapy in HIV-1-infected patients carrying the CCR5 Delta32 deletion (English)

1 reference

3 August 2017

0 references

4

Rouzioux C

1 reference

3 August 2017

Laurichesse JJ

1

1 reference

3 August 2017

Persoz A

2

1 reference

3 August 2017

Theodorou I

3

1 reference

3 August 2017

Delfraissy JF

5

1 reference

3 August 2017

Meyer L

6

1 reference

3 August 2017

publication date

1 May 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

8

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

213-219

1 reference

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

CCR5 delta32 deletion and reduced risk of toxoplasmosis in persons infected with human immunodeficiency virus type 1. The SEROCO-HEMOCO-SEROGEST Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Association of highly active antiretroviral therapy failure with chemokine receptor 5 wild type

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Treatment history and baseline viral load, but not viral tropism or CCR-5 genotype, influence prolonged antiviral efficacy of highly active antiretroviral treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

CC chemokine receptor 5 delta32 and CC chemokine receptor 2 64I polymorphisms do not influence the virologic and immunologic response to antiretroviral combination therapy in human immunodeficiency virus type 1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

CD4+ T cell surface CCR5 density as a determining factor of virus load in persons infected with human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Role for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Short-Term CD4 Cell Response After Highly Active Antiretroviral Therapy Initiated at Different Times From Seroconversion in 1500 Seroconverters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

CCR5Δ32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

Molecular and Clinical Epidemiology of CXCR4‐Using HIV‐1 in a Large Population of Antiretroviral‐Naive Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

HIV-1 infection in a man homozygous for CCR5▵32

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2007.00455.X

10.1111/J.1468-1293.2007.00455.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference